Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171776 | 0.79 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL30438289 | 0.79 | MEN1 (0.37) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL26289615 | 0.79 | MEN1 (0.37) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL11614203 | 0.78 | MEN1 (0.39) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL27463611 | 0.76 | KDM4E (0.57) | MAPTNPC1RAB9A | |
| SCHEMBL14214763 | 0.76 | IDH1 (0.40) | — | |
| SCHEMBL1271374 | 0.71 | — | — | |
| SCHEMBL2324857 | 0.71 | IDO1 (0.45) | MAP4K4 | |
| SCHEMBL17601433 | 0.69 | HSP90AA1 (0.41) | GABRA1GABRG2GABRB3GABRA3MEN1 | |
| SCHEMBL445042 | 0.68 | MEN1 (0.59) | GABRA1GABRG2GABRB3GABRA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205086-B1 | FUNGICIDAL HETEROCYCLIC AMINES | DU PONT (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | E.I. DU PONT NEMOURS AND COMPANY (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026359-B2 | Fungicidal heterocyclic amines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2205086-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. du Pont de Nemours and Company (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009061761-A2 | FUNGICIDAL HETEROCYCLIC AMINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267729-A1 | FUNGICIDAL HETEROCYCLIC AMINES | PRMT9, MAOB, CYP2C9 | GABRA1 2896/4885GABRG2 2297/4885GABRB3 2651/4885 |
| US-20110301123-A1 | Fungicidal Heterocyclic Amines | PRMT9, MAOB, CYP2C9 | GABRA1 2896/4885GABRG2 2297/4885GABRB3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.